ClinicalTrials.gg
RecruitingNCT07388498Updated Oct 19, 2026

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

A Phase 3 interventional study of Pegloticase and Methotrexate in Uncontrolled Gout, sponsored by Amgen. Recruiting at 75 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 19, 202610 sites added6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Planned enrollment
2nd of 14
270 · median 93
Started
2026
the only one that year
Phase 3
4 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 3, and was the 14th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries.

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained normalization of serum uric acid (sUA) to \< 6 mg/dL for at least 80% of the time during Month 6.

03

Conditions studied

  • Uncontrolled Gout

Browse trials for

Keywords

  • Uncontrolled Gout
  • Pegloticase
  • KRYSTEXXA
  • Kadence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided before initiation of any trial-specific activities/procedures.
  • Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.
  • Participants willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
  • Participants with uncontrolled gout, as meeting the protocol defined criteria.

Exclusion criteria

Exclusion Criteria

  • Glucose-6-phosphate dehydrogenase deficiency (tested at the screening visit).
  • Liver transaminase levels ( [AST] or alanine aminotransferase [ALT]) > 1.25 x (ULN) or albumin \< the lower limit of normal (LLN) at the screening visit.
  • Uncontrolled diabetes mellitus and/or (HbA1c) > 8%.
  • Known intolerance to MTX.
  • Participant received prior treatment with pegloticase, another recombinant uricase (ie, rasburicase or pegadricase), or concomitant therapy with a polyethylene glycol (PEG)-conjugated drug.
  • A known intolerance to all protocol standard gout flare prophylaxis regimens (ie, participant must be able to tolerate at least 1 of the following: colchicine and/or non-steroidal anti-inflammatory drug and/or low-dose prednisone ≤ 10 mg/day or equivalent dose of other ).
  • Chronic renal impairment defined as estimated (eGFR) based on Modification of Diet in Renal Disease (MDRD) calculations \< 40 mL/min/1.73 m\^2 or currently on dialysis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Pegloticase SC with MTX

    Participants will receive pegloticase SC every two weeks with MTX.

    Drug: Pegloticase · Drug: Methotrexate

  • Experimental
    Pegloticase IV with MTX

    Participants will receive pegloticase IV every two weeks with MTX.

    Drug: Pegloticase · Drug: Methotrexate

Interventions

  • Participants will receive pegloticase either SC or IV.

    Also known as: KRYSTEXXA

  • MTX will be administered orally.

    Also known as: MTX

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24

    Defined as Achieving and Maintaining sUA \< 6 mg/dL for at Least 80% of the Time During Month 6.

    Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)

Secondary outcomes

  1. Number of Participants With Serious Injection Site Reactions Through Week 48

    Time frame: Up to Week 48

  2. Number of Participants With Serious Adjudicated Infusion Reactions (Including Adjudicated Anaphylaxis) Through Week 48

    Time frame: Up to Week 48

  3. Number of Participants With Adjudicated Anaphylaxis Through Week 48

    Time frame: Up to Week 48

  4. Serum Concentrations of Pegloticase Following SC and IV Administration

    Time frame: Up to Week 48

07

Study locations

75 of 75 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
    Recruiting
  • Unity Health Searcy Medical Center
    Searcy, Arkansas 72143, United States
    Recruiting
  • Precision Rheumatology
    Anaheim, California 92802, United States
    Recruiting
  • Advanced Clinical Research Center, LLC dba TriWest Research Associates
    Chula Vista, California 91910, United States
    Recruiting
  • Veterans Affairs Long Beach Health Care System
    Long Beach, California 90822, United States
    Recruiting
  • Solace Clinical Research
    Tustin, California 92780, United States
    Recruiting
  • Jiva Health
    Walnut Creek, California 94598, United States
    Recruiting
  • Denver Arthritis Clinic PC
    Denver, Colorado 80230, United States
    Recruiting
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
    Recruiting
  • D and H Pompano Research Center
    Aventura, Florida 33180, United States
    Recruiting
  • Bay Pines Veterans Affairs Healthcare System
    Bay Pines, Florida 33744, United States
    Recruiting
  • Discovery Health Research Center
    Coral Springs, Florida 33065, United States
    Recruiting
  • Hillcrest Medical Research
    DeLand, Florida 32720, United States
    Recruiting
  • New Generation of Medical Research
    Hialeah, Florida 33016, United States
    Recruiting
  • Homestead Associates In Research Inc
    Homestead, Florida 33033, United States
    Recruiting
  • Decision Management International Research
    Largo, Florida 33774, United States
    Recruiting
  • Pharmax Research Clinic
    Miami, Florida 33126, United States
    Recruiting
  • Well Pharma Medical Research Corp
    Miami, Florida 33143, United States
    Recruiting
  • D and H National Research Centers
    Miami, Florida 33155, United States
    Recruiting
  • Advanced Clinical Research
    Miami, Florida 33156, United States
    Recruiting
  • Entrust Clinical Research
    Miami, Florida 33176, United States
    Recruiting
  • Felicidad Medical Research
    Miami, Florida 33184, United States
    Recruiting
  • Integral Rheumatology and Immunology Specialists
    Plantation, Florida 33324, United States
    Recruiting
  • D and H Tamarac Research Center
    Tamarac, Florida 33321, United States
    Recruiting
  • Nodal Medical Center Research
    Tampa, Florida 33607, United States
    Recruiting
  • ClinPro Research Solutions LLC
    Tampa, Florida 33609, United States
    Recruiting
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
    Recruiting
  • Conquest Research - Winter Park
    Winter Park, Florida 32789, United States
    Recruiting
  • Spatium Urgent Care
    Marietta, Georgia 30066, United States
    Recruiting
  • Vista Clinical Research
    Newnan, Georgia 30265, United States
    Recruiting
  • Greater Chicago Specialty Physicians
    Boise, Idaho 83702, United States
    Recruiting
  • Saint Lukes Intermountain Research Center
    Meridian, Idaho 83642, United States
    Recruiting
  • Charter Research
    Chicago, Illinois 60618, United States
    Recruiting
  • Flourish Research Ravenswood
    Chicago, Illinois 60640, United States
    Recruiting
  • Willow Rheumatology and Wellness
    Willowbrook, Illinois 60527, United States
    Recruiting
  • Clinical Trials Management, LLC, d/b/a Flourish Research
    Mandeville, Louisiana 70471, United States
    Recruiting
  • Kur Research at Columbia Medical Practice
    Columbia, Maryland 21045, United States
    Recruiting
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
    Recruiting
  • June DO PC
    Lansing, Michigan 48910, United States
    Recruiting
  • Clinical Research Institute of Michigan
    Saint Clair Shores, Michigan 48081, United States
    Recruiting
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Missouri 64128, United States
    Recruiting
  • Bioluminux Clinical Research - Hamilton
    Hamilton, New Jersey 08690, United States
    Recruiting
  • Raymond G Murphy Veteran Affairs Medical Center
    Albuquerque, New Mexico 87108, United States
    Recruiting
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
    Recruiting
  • Buffalo Rheumatology and Medicine
    Orchard Park, New York 14127, United States
    Recruiting
  • Arthritis and Osteoporosis Consultants of the Carolinas
    Charlotte, North Carolina 28202, United States
    Recruiting
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Onsite Clinical Solutions, LLC
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
    Recruiting
  • Triad Clinical Trials, LLC
    Greensboro, North Carolina 27410, United States
    Recruiting
  • Cape Fear Arthritis Care, PLLC
    Leland, North Carolina 28451, United States
    Recruiting
  • Accellacare Salisbury
    Salisbury, North Carolina 28144, United States
    Recruiting
  • Carolina Research Center Inc
    Shelby, North Carolina 28150, United States
    Recruiting
  • Shelby Clinical Research
    Shelby, North Carolina 28150, United States
    Recruiting
  • The Ohio State University
    Columbus, Ohio 43203, United States
    Recruiting
  • Paramount Medical Research and Consulting LLC
    Middleburg Heights, Ohio 44130, United States
    Recruiting
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73111, United States
    Recruiting
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Articularis Healthcare Group Inc dba Low Country Rheumatology
    Summerville, South Carolina 29486, United States
    Recruiting
  • Health Concepts
    Rapid City, South Dakota 57702, United States
    Recruiting
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
    Recruiting
  • Pioneer Research Solutions Inc
    Bellaire, Texas 77401, United States
    Recruiting
  • Southwest Rheumatology
    Dallas, Texas 75230, United States
    Recruiting
  • Research Physicians Network, LLC
    Houston, Texas 77089, United States
    Recruiting
  • Texas Arthritis & Rheumatology Associates
    Katy, Texas 77450, United States
    Recruiting
  • Biopharma Informatic, LLC
    Katy, Texas 77494, United States
    Recruiting
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
    Recruiting
  • Be Well Clinical Studies
    Round Rock, Texas 78681, United States
    Recruiting
  • Siena Research Network
    Sugar Land, Texas 77479, United States
    Recruiting
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
    Recruiting
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
    Recruiting
  • Overlake Arthritis and Osteoperosis Center
    Bellevue, Washington 98004, United States
    Recruiting
  • Caribbean Health Research Center
    San Juan, 00917, Puerto Rico
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Jun 18, 2028
CompletionEst.
Jun 18, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 6 sites removed
Show 10 added (10 United States)
  • Unity Health Searcy Medical Center · Searcy, United States
  • Veterans Affairs Long Beach Health Care System · Long Beach, United States
  • Jiva Health · Walnut Creek, United States
  • Decision Management International Research · Largo, United States
  • Greater Chicago Specialty Physicians · Boise, United States
  • Saint Lukes Intermountain Research Center · Meridian, United States
  • University of Kansas Medical Center · Kansas City, United States
  • The Ohio State University · Columbus, United States
  • Pioneer Research Solutions Inc · Bellaire, United States
  • Advanced Rheumatology of Houston · The Woodlands, United States
Show 6 removed
  • Decision Management International Research · Pinellas Park, United States
  • Saint Lukes Intermountain Research Center · Boise, United States
  • Greater Chicago Specialty Physicians · Schaumburg, United States
  • Ohio State University Wexner Medical Center Clinical Research Center · Columbus, United States
  • Pioneer Research Solutions Inc · Houston, United States
  • Arthritis Northwest Professional Limited Liability Company · Spokane, United States
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    10 sites added, 6 sites removed
    Show 10 added (10 United States)
    • Unity Health Searcy Medical Center · Searcy, United States
    • Veterans Affairs Long Beach Health Care System · Long Beach, United States
    • Jiva Health · Walnut Creek, United States
    • Decision Management International Research · Largo, United States
    • Greater Chicago Specialty Physicians · Boise, United States
    • Saint Lukes Intermountain Research Center · Meridian, United States
    • University of Kansas Medical Center · Kansas City, United States
    • The Ohio State University · Columbus, United States
    • Pioneer Research Solutions Inc · Bellaire, United States
    • Advanced Rheumatology of Houston · The Woodlands, United States
    Show 6 removed
    • Decision Management International Research · Pinellas Park, United States
    • Saint Lukes Intermountain Research Center · Boise, United States
    • Greater Chicago Specialty Physicians · Schaumburg, United States
    • Ohio State University Wexner Medical Center Clinical Research Center · Columbus, United States
    • Pioneer Research Solutions Inc · Houston, United States
    • Arthritis Northwest Professional Limited Liability Company · Spokane, United States
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07388498
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Feb 9, 2026
Primary completion
Jun 18, 2028 (estimated)
Completion
Jun 18, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion